The Role of Hippocampal Sclerosis in Topiramate-related Depression and Cognitive Deficits in People with Epilepsy

Epilepsia

Volumn 44, Issue 12, 2003, Pages 1573-1577

  Mula, Marco ^a,b   Trimble, Michael R ^a   Sander, Josemir W A S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Adverse events; Depression; Epilepsy; Hippocampal sclerosis; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; TOPIRAMATE;

ADULT; AGGRESSION; ANXIETY; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIPPOCAMPAL SCLEROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; REGRESSION ANALYSIS; RISK FACTOR; SCLEROSIS; TEMPORAL LOBE EPILEPSY; TITRIMETRY;

ADULT; ANTICONVULSANTS; COGNITION DISORDERS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; EPILEPSY, TEMPORAL LOBE; FEMALE; FRUCTOSE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SCLEROSIS;

EID: 0346103740     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2003.19103.x     Document Type: Article

References (32)

1. Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:1164-73.
2. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, 600-mg dosages. Neurology 1996;46:1684-90.
3. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, 1000-mg dosages. Neurology 1996;46:1678-83.
4. Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:763-8.
5. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
6. Sharieff M, Viteri C, Ben-Menachem E, et al. Double-blind placebo-controlled study of topiramate in patients with refractory seizures. Epilepsy Res 1996;25:217-24.
7. Sachdeo RC, Glauser TA, Ritter RC, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882-7.
8. Biton V, Montouris GD, Ritter F. A study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7.
9. Tatum WO, French JA, Morris GL, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
10. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
11. Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003;60:1104-7.
12. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-63.
13. Tebartz van Elst L, Woermann FG, Lemieux L, et al. Amygdala enlargement in dysthymia: a volumetric study of patients with temporal lobe epilepsy. Biol Psychiatry 1999;46:1614-23.
14. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry 2000;157:115-8.
15. Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002;159:1112-8.
16. Falconer MA, Taylor DC. Surgical treatment of drug-resistant epilepsy due to mesial temporal sclerosis. Arch Neurol 1968;19:353-61.
17. Duncan JS, Sagar HJ. Seizure characteristics, pathology, and outcome after temporal lobectomy. Neurology 1987;37:405-9.
18. French JA, Williamson PD, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy, I: results of history and physical examination. Ann Neurol 1993;34:774-80.
19. Kanemoto K, Takeuchi J, Kawasaki J, et al. Characteristics of temporal lobe epilepsy with mesial temporal sclerosis, with special reference to psychotic episodes. Neurology 1996;47:1199-203.
20. Hermann BP, Seindemberg M, Schoenfeld J, et al. Neuropsychological characteristics of the syndrome of mesial temporal lobe epilepsy. Arch Neurol 1997;54:369-76.
21. Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41:338-41.
22. Duncan JS. Imaging and epilepsy. Brain 1997;120:339-77.
23. Commission on Neuroimaging of the International League Against Epilepsy. Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997;38:1255-6.
24. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for a revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
25. Engel J Jr. Mesial temporal lobe epilepsy: what have we learned? Neuroscientist 2001;7:340-52.
26. Martin R, Dowler R, Ho S, et al. Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis. Neurology 1999;53:709-15.
27. Dimen S, Matthews CG, Harley JP. Effect of early versus late onset of major motor epilepsy upon cognitive-intellectual performance: further considerations. Epilepsia 1977;18:31-6.
28. Kanner MA, Faught E, French AJ, et al. Psychiatric adverse events caused by topiramate and lamotrigine: a postmarketing prevalence and risk factor study [Abstract]. Epilepsia 2000;41(suppl 7):169.
29. Trimble MR. Clinical presentations in neuropsychiatry. Semin Clin Neuropsychiatry 2002;7:11-7.
30. Schmitz EB, Robertson MM, Trimble MR. Depression and schizophrenia in epilepsy: social and biological risk factors. Epilepsy Res 1999;35:59-68.
31. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-43.
32. Quiske A, Helmsteadter C, Lux S, et al. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000;391:121-5.